These discrepancies could in part be explained by differences in study design, as the PRIME-NET study included patients with PD at enrollment, with well-differentiated G1-G2 pancreatic tumors (associated with an aggressive clinical course), and patients received more active antitumor therapies (i.e., somatostatin analogs with or without everolimus), while in the CLARINET study patients had stable disease at enrollment, tumors of different primary origin (including panNETs and intestinal NETS with a Ki67 ≤ 10%), and received single-agent treatment with lanreotide or placebo. This evidence concerns the gene MKI67 and intestinal neuroendocrine neoplasm.